Treatment for epilepsy in pregnancy: Neurodevelopmental outcomes in the child

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 10, 2014, Pages

  Bromley, Rebecca ^a   Weston, Jennifer ^b   Adab, Naghme ^c   Greenhalgh, Janette ^b   Sanniti, Anna ^b   Mckay, Andrew J ^d   Tudur Smith, Catrin ^b   Marson, Anthony G ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c WALSGRAVE HOSPITAL   (United Kingdom)

^d ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; LEVETIRACETAM; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; ANTICONVULSIVE AGENT;

AGE; AUTISM; CHILD; CLINICAL OUTCOME; COGNITION; DEVELOPMENTAL QUOTIENT; DEVELOPMENTAL, AGE AND GROWTH PARAMETERS; DRUG EFFECT; DRUG EFFICACY; EPILEPSY; HUMAN; INTELLIGENCE QUOTIENT; LANGUAGE; MEMORY; MENTAL PERFORMANCE; NERVE CELL DIFFERENTIATION; PREGNANCY; PRENATAL EXPOSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK; SKILL; SYSTEMATIC REVIEW; CHEMICALLY INDUCED; DEVELOPMENTAL DISORDER; DRUG EFFECTS; FEMALE; INTELLIGENCE; META ANALYSIS; PREGNANCY COMPLICATIONS; PROSPECTIVE STUDY;

AGE FACTORS; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; DEVELOPMENTAL DISABILITIES; EPILEPSY; FEMALE; HUMANS; INTELLIGENCE; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VALPROIC ACID;

EID: 84964698399     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010236.pub2     Document Type: Review

References (145)

1. Arulmozhi T, Dhanaraj M, Rangaraj R, Vengatesan A. Physical growth and psychomotor development of infants exposed to antiepileptic drugs in utero. Neurology India 2006;54(1):42-6.
2. Bromley R. Personal communication with R. Bromley. 2013.
3. Bromley R, Mawer G, Love J, Kelly J, Purdy L, McEwan L, et al.Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia 2010;51(10):2058-65.
4. Bromley R. Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology 2008;71:1923-5.
5. Bromley R, Mawer G, Briggs M, et al.The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery, and Psychiatry 2013;84(6):637-43.
6. Cummings C. Personal communication with C Cummings. 2013.
7. Cummings C, Stewart M, Stevenson M, Morrow M, Nelson J. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood 2011;96:643-7.
8. D'Souza S, Robertson I, Donnai D, Mawer G. Fetal phenytoin exposure, hypoplastic nails, and jitteriness. Archives of Disease in Childhood 1990;65:320-4.
9. Eriksson K, Viinikainen K, Monkkonen A, Aikia M, Nieminen P, Heinonen, et al.Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Research 2005;65:189-200.
10. Viinikainen K. The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy and Behavior 2006;9:636-40.
11. Gaily E, Kantola-Sorsa E, Granstrom M. Intelligence of children of epileptic mothers. The Journal of Pediatrics 1988;113(4):677-84.
12. Gaily E, Kantola-Sorsa E, Granstrom M. Specific cognitive dysfunction in children with epileptic mothers. Developmental Medicine and Child Neurology 1990;32:403-14.
13. Granstrom M. Development of the children of epileptic mothers: Preliminary results from the prospective Helskiinki Study. Epilepsy, Pregnancy, and the Child. 1982. New York: Raven Press.
14. Gaily E, Kantola-Sorsa E, Hiilesmaa V, et al.Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004;62:28-32.
15. Kantola-Sorsa E, Gaily E, Isoaho M, Korkman M. Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society 2007;13:642-52.
16. Hattig H, Helge H, Steinhausen HC. Infants of epileptic mothers: Developmental scores at 18 months. Advances in Epileptology. Vol. 16, New York: Raven Press, 1987:549-81.
17. Hattig H, Steinhausen HC. Psychobiology and Early Development. North Holland: Elsevier Science Publishers, 1987.
18. Jager Roman S, Fating D, Koch, et al.Somatic parameters, diseases and psychomotor development in the offspring of epileptic parents. Pregnancy, Epilepsy, and the Child. New York: Raven Press, 1982:425-32.
19. Koch S, Jager-Roman E, Losche G, Nau H, Rating D, Helge H. Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatrica 1996;84:739-46.
20. Koch S, Titze K, Zimmerman R, Schroder M, Lehmkuhl U, Rauh H. Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia 1999;40(9):1237-43.
21. Losche G, Steinhausen HC, Koch S, Helge H. The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatrica 1994;83:961-6.
22. Rating D, Nau H, Jager-Roman E, Gopfert-Geyer I, Kock S, Beck-Mannagetta G, et al.Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatrica Scandinavica 1982;71(2):301-11.
23. Steinhausen HC, Losche G, Kock S, Helge H. The psychological development of children of epileptic parents. 1. Study design and comparative findings. Acta Paediatrica 1994;83:955-60.
24. Titze K, Koch S, Helge H, Lehmkuhl U, Rauh H, Steinhausen HC. Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental Medicine and Child Neurology 2008;50:117-22.
25. Hanson J, Myrianthopoulos N, Harvey M, Smith D. Risks to offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. Journal of Pediatrics 1976;89(4):662-8.
26. Hill R, Verniaud W, Horning M, McCulley L, Morgan N. Infants exposed in utero to antiepileptic drugs: A prospective study. American Journal of Diseases in Childhood 1974;127:645-53.
27. Hill R, Verniaud W, Rettig G, Tennyson L, Craig J. Relationship between antiepileptic drug exposure of the infant and developmental potential. In: Janz, et al. editor(s). Epilepsy, Pregnancy, and the Child. New York: Raven Press, 1982:409-17.
28. Fujioka K, Kaneko S, Hirano T, et al.A study of the psychomotor development of the offspring of epileptic mothers. 1984.
29. Hirano T, Fujioka K, Okada M, Iwasa H, Kaneko S. Physical and psychomotor development in the offspring born to mothers with epilepsy. Epilepsia 2004;45 Suppl 8:53-7.
30. Nomura Y, Takebe Y, Nomura Y, Shinagawa S, Kaneko S, Sato T. The physical and mental development of infants born to mothers treated with antiepileptic drugs. 1984.
31. James F, Walshaw D, Kelly T, Lynch S, Jackson M. Neurodevelopmental outcome of infants born to mothers taking antiepileptic drugs in pregnancy: Results of a prospective population based study in the North of England.
32. Jones K, Lacro R, Johnson K, Adams J. Patern of malformations in the children of women treated with carbamazepine during pregnancy. The New England Journal of Medicine 1989;320(25):1661-6.
33. Leavitt A, Yerby M, Robinson N, Sells C, Erickson D. Epilepsy in pregnancy: developmental outcome of offspring at 12 months. Neurology 1992;42(5):141-3.
34. Nadebaum C, Anderson V, Vajda F, Reutens D, Barton S, Wood A. Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology 2011;76:719-26.
35. Nadebaum C, Anderson V, Vajda F, Reutens D, Barton S, Wood A. The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. Journal of the International Neuropsychological Society 2011;17:133-42.
36. Cohen M, Meador K, Browning N, et al.Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy and Behavior 2011;22:240-6.
37. McVearry K, Gaillard W, VanMeter J, Meador K. A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy and Behavior 2009;16:609-16.
38. Meador K, Baker G, Browning N, et al.Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine 2009;360(16):1597-605.
39. Meador K, Baker G, Browning N, et al.Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology 2013;12:244-52.
40. Meador K, Baker G, Browning N, et al.Foetal antieplieptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain 2011;134:396-404.
41. Meador K, Baker G, Browning N, et al.Relationship of child IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior 2011;21:147-52.
42. Meador K, Browning N, Cohen M, et al.In utero antiepileptic drugs: differential cognitive outcomes in children of women with epilepsy. American Epilepsy Society. 2006.
43. Ornoy A, Cohen E. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Archives of Disease in Childhood 1996;75:517-20.
44. Regesta T. The risk of malformations and developmental disturbances in children exposed to antiepileptic drugs: a prospective controlled study. Bollettino Lega Italiana Epilessia 1996;95(96):351-4.
45. Tanganelli P, Regesta G. Epilepsy, pregnancy, and major birth anomalies: An Itialian prospective controlled study. Neurology 1992;42 Suppl 5:89-93.
46. Rihtman T, Parush S, Ornoy A. Preliminary findings of the developmental effects of in utero exposure to topiramate. Reproductive Toxicology 2012;34(3):308-11.
47. Rihtman T, Parush S, Ornoy A. Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reproductive Toxicology 2013;41:115-25.
48. Gladstone D, Bologa M, Maguire C, Pastuszak A, Koren G. Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin; a prospective study. Reproductive Toxicology 1992;6:257-61.
49. Rovet J, Cole S, Nulman I, Scolnik D, Altmann D, Koren G. Effects of maternal epilepsy on children's neurodevelopment. Child Neuropsychology 1995;1(2):150-7.
50. Scolnik D, Nulman I, Rovet J, Gladstone D, Czuchta D, et al.Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 1994;271(10):767-70.
51. Shallcross R. Child development following In utero exposure: A comparison of novel and established antiepileptic drug treatment. Thesis: University of Liverpool. Liverpool, 2011.
52. Shallcross R, Bromley R, Irwin B, Bonnett L, Morrow J, Baker G. Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology 2011;76:383-9.
53. Shallcross R, Bromley RL, Cheyne CP, et al.In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology 2014;82:213-21.
54. Sobczyk W, Dowzenko A, Krasicka J. Investigation of children of mothers treated in pregnancy with anticonvulsants. Neurologia i Neurochirurgia Polska 1977;11(1):59-63.
55. Thomas S, Sukumaran S, Lukose N, George A, Sarma P. Intellectual and language functions in children of mothers with epilepsy. Epilepsia 2007;48(12):2234-40.
56. Thomas S, Ajaykumar B, Singhu K, Nair M, George B, Sarma P. Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy and Behavior 2008;13:229-36.
57. Veiby G, Daltveit A, Schjolberg S, Stoltenberg C, Oyen A-S, Vollset S, et al.Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia 2013;54(8):1462-72.
58. Wide K, Henning E, Eomson T, Winbladh B. Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatrica 2002;91:409-14.
59. Wide K, Winbladh B, Tomson T, Sars-Zimmer K, Berggren E. Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. Developmental Medicine and Child Neurology 2000;42:87-92.
60. Annegers J, Elveback L, Hauser A, Kurland L. Do anticonvulsants have a teratogenic effect?. Archives of Neurology 1974;31:364-73.
61. Antiga E, Monetti V, Fallica E, et al.Cognitive development in children born to mothers with epilepsy [Epilessia e gravidanza: valutazione dello sviluppo cognitivo nei bambini nati da donne con epilessia]. Bollettino Lega Italiana Epilessia 2010;140:154-5.
62. Dean J, Hailey H, Moore S, Lloyd D, Turnpenny P, Little J. Long term and health and neurodevelopment in children exposed to antiepileptic drugs before birth. Journal of Medical Genetics 2002;36:251-9.
63. Dessens A, Cohen-Kettenis P, Mellenbergh G, Koppe J, van de Poll N, Boer K. Association of prenatal phenobarbital and phenytoin exposure with small head size at birth with learning problems. Acta Paediatrica 2000;89:533-41.
64. Forsberg L, Wide K, Kallen B. School performance at age 16 in children exposed to antiepileptic drugs in utero - A population-based study. Epilepsia 2011;52(2):364-9.
65. Holmes L, Rosenberger P, Harvey E, Khoshbin S, Ryan L. Intelligence and physical features of children of women with epilepsy. Teratology 2000;61:196-202.
66. Holmes L, Coull B, Dorfman J, Rosenberger P. The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. Journal of Pediatrics 2005;146:118-22.
67. Jakubowska T, Koziak M, Lipczynska-Lojkowska W, Niedzielska K, Witkowska-Olearska K, Zielinski J. Health status of children born to mothers with epilepsy [Ocena stanu zdrowia dzieci matek chorych na padaczke]. Neurologia i Neurochirurgia Polska 1981;15(3):303-8.
68. Kelly T, Edwards P, Rein M, Miller J, Dreifuss F. Teratogenicity of anticonvulsant drugs 2: a prospective study. American Journal of Medical Genetics 1984;19:435-43.
69. Kozhokaru A, Karlov V, Zhydkova I, Serkina A. Intellectual, psychomotor and speech development of children born to mothers with epilepsy. Zhurnal Nevropatologii i Psikhiatrii Imeni 2010;110(2):25-30.
70. Latis G, Battino D, Boldi B, et al.Preliminary data of a neuropediatric follow-up of infants born to epileptic mothers. In: Janz, et al. editor(s). Epilepsy, Pregnancy and the Child. New York: Raven Press, 1982:419-23.
71. Lekwuwa G, Adewole I, Thompson M. Antiepileptic drugs and teratogenicity in Nigerians. Transanction of the Royal Society of Tropical Medicine and Hygiene 1995;89:227.
72. Majewski F, Steger M, Richter B, Gill J, Rabe F. The teratogenicity of hydantoins and barbiturates in humans, with considerations on the etiology of malformations and cerebral disturbances in the children of epileptic parents. Biological Research in Pregnancy 1981;2(1):94-102.
73. Meador K, Baker G, Browning N, et al.Effects of breastfeeding in children of women taking antiepileptic drugs. Neurology 2010;75:1954-60.
74. Moore S, Turnpenny P, Quinn A, et al.A clinical study of 57 children with fetal anticonvulsant syndromes. Journal of Medical Genetics 2000;37:489-97.
75. Mortensen E, Reinisch J, Sanders S, Rubin D. Intelligensdefekter som senfølge af praenatal eksposition for phenobarbital fenemal. [Delayed effects of prenatal exposure to phenobarbital on intelligence Phenemal]. Ugeskrift for Laeger 1996;158(46):6589-94.
76. Reinisch J, Sanders S, Mortensen E, Rubin D. In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA 1995;274(19):1518-25.
77. Mortensen J, Olsen J, Larsen H, Bendsen, Obel C, Sorensen H. Psychomotor development in children exposed in utero to benzodiazepines, antidepressants, neuroleptics, and anti-epileptics. European Journal of Epidemiology 2003;18:769-71.
78. Oyen N, Vollset S, Eide M, Bjerkedal T, Skjaerven R. Maternal epilepsy and offsprings' adult intelligence: A population-based study from Norway. Epilepsia 2007;48(9):1731-8.
79. Parisi P, Francia A, Vanacore N, Fiore S, Gillonardo A, Manfredi M. Psychomotor development and general movements in offspring of women with epilepsy and anticonvulsant therapy. Early Human Development 2003;74:97-108.
80. Perinola T, Buttiglione M, Margari L. Antiepileptic drugs in pregnancy: late effects on the children's cognitive abilities. Acta Neurologia 1992;14(4-6):543-6.
81. Rasalam A, Hailey H, Williams J, et al.Characteristics of fetal anticonvulsant syndrome associated autistic disorder. Developmental Medicine and Child Neurology 2005;47:551-5.
82. Sereno-Colo J, Dominguez F, Gutierrez J. [Tratamiento de la gestante epileptica con carbamacepina]. Ginecologia y Obstetricia de Mexico 1984;52(329):231-5.
83. Steinhausen HC, Nestler V, Huth H. Psychopathology and mental functions in the offspring of alcoholic and epileptic mothers. Journal of the American Academy of Child Psychiatry 1982;21(3):268-73.
84. Vanoverloop D, Schnell R, Harvey E, Holmes L. The effects of prenatal exposure to phenytoin and other anticonvulsants on intellectual function at 4 to 8 years of age. Neurotoxicology and Teratology 1992;14:329-35.
85. Deblay M, Vert P, Andre M. Children of epileptic mothers [L'enfant de mere epileptique]. La Nouvelle Presse Mediciale 1982;11(3):173-6.
86. Vert P, Deblay M, Andre M. Follow-up study on growth and neurologic development of children born to epileptic mothers. In: Janz, et al. editor(s). Epilepsy, Pregnancy, and the Child. New York: Raven Press, 1982:433-6.
87. Yamatogi Y, Oka E, Satoh M, Kobayashi K, Yoshinaga H, Ohtahara S. A prospective follow-up of the offspring of epileptic patients. The Japanese Journal of Psychiatry and Neurology 1993;47(2):309-11.
88. Adams JHE, Holmes LB. Cognitive deficits following gestational monotherapy with phenobarbital and carbamazepine. Neurotoxicology and Teratology 2000;22:466.
89. Jovic N, Knezevic-Pogancev M, Ignjatovic MP. Cognitive functions at 6 years of age after fetal exposure to antiepileptic drugs used in mothers with juvenile myoclonic epilepsy. European Neuropsychopharmacology 2011;21(2):169.
90. Nadebaum C, Anderson V, Vajda F, Wood A. Academic achievement of Australian children prenatally exposed to antiepileptic drugs. International Epilepsy Congress. 2011.
91. Wood AG, Nadebaum C, Anderson VA, Reutens D, Barton S, O'Brien T, Vajda FV. Valproate dose is an independent risk factor for autism spectrum disorder: Evidence from prospective assessments in the Australian brain, cognition and antiepileptic drugs study. 29th International Epilepsy Congress.
92. Ackers R, Besag FM, Wade A, Murray ML, Wong IC. Changing trends in antiepileptic drug prescribing in girls of child-bearing potential. Archive of Disease in Childhood 2009;94(6):443-7.
93. Adab N, Jacoby A, Smith D, Chadwick D. Additional educational needs in children born to mothers with epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry 2001;70(1):15-21.
94. Adab N, Tudur Smith C, Vinten J, Williamson PR, Winterbottom JB. Common antiepileptic drugs in pregnancy in women with epilepsy. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD004848].
95. Adab N, Kini U, Vinten J, Ayres J, Baker G, Clayton-Smith J, et al.The longer term outcome of children born to mothers with epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry 2004;75(11):1575-83.
96. Ardinger H, Atkin J, Blackston R, Elsas L, Clarren S, Livingstone S, et al.Verification of the fetal valproate syndrome phenotype. American Journal of Medical Genetics 1988;29(1):171-85.
97. Arndt TL, Stodgell CJ, Rodier PM. The teratology of autism. International Journal of Developmental Neuroscience 2005;23(2-3):189-99.
98. Banach R, Boskovic R, Einarson T, Koren G. Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs. A meta-analysis of cohort studies. Drug Safety 2010;33(1):73-9.
99. Baron I. Neuropsychological Evaluation of the Child. Oxford: Oxford University Press, 2004.
100. Bittigau P, Sifringer M, Ikonomidou C. Antiepileptic drugs and apoptosis in the developing brain. Annals of the New York Academy of Sciences 2003;993:103-14.
101. Bossi L. Neonatal period including drug disposition in new borns: Review of the literature. In: Janz D, Dam M, Richens A, Bossi L, Helge H, Schmidt D editor(s). Epilepsy, Pregnancy and the Child. New York: Ravens press, 1982:327-42.
102. Brent R. Environmental causes of human congenital malformations: the pediatrician's role in dealing with these complex clinical problems caused by a multiplicity of environmental and genetic factors. Pediatrics 2004;13(4):957-68.
103. Bromley RL, Baker GA, Meador KJ. Cognitive abilities and behaviour of children exposed to antiepileptic drugs in utero. Current Opinion in Neurology 2009;22:162-6.
104. Bromley RL, Mawer G, Love J, Kelly J, Purdy L, McEwan L, et al.Early cognitive development in children born to women with epilepsy: A prospective report. Epilepsia 2010;51(10):2058-65.
105. Charlton RA, Weil JG, Cunnington MC, Ray S, de Vries CS. Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations. Drug Safety 34;2:157-71.
106. Chevallier B, Negre V, Bidat E, Lagardere B. Fetal valproate syndrome and somatic and psychomotor development. Archives Francaises Pediatrie 1989;46:627-30.
107. Christensen J, Gronborg TK, Sorensen MJ, Schendel D, Parner ET, Pedersen LH, Vestergaard M. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013;309(16):1696-703.
108. Christianson A, Chesler N, Kromberg J. Fetal valproate syndrome: Clinical and neurodevelopmental features in two sibling pairs. Developmental Medicine and Child Neurology 1994;36:357-69.
109. Clayton-Smith J, Donnai D. Fetal valproate syndrome. Journal of Medical Genetics 1995;32:724-7.
110. Cummings C, Stewart M, Stevenson M, Morrow J, Nelson J. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of Disease in Childhood 2011;96:943-7.
111. Dean JCS, Hailey H, Moore SJ, Lloyd DJ, Turnpenny PD, Litttle J. Long term health and neurodevelopment in children with prenatal exposure to antiepileptic drugs before birth. Journal of Medical Genetics 2002;39:251-9.
112. Deary IJ, Stran S, Smith P, Fernandes C. Intelligence and educational achievement. Intelligence 2007;35:13-21.
113. Friedman JM. ABCDXXX: The obscenity of postmarketing surveillance for teratogenic effects. Birth Defects Research A. Clinical and Molecular Teratology 2012;94(8):670-6.
114. Gaily E, Kantola-Sorsa E, Hiilesmaa V, Isoaho M, Matila R, Kotila M. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004;62:28-32.
115. Guyatt GH, Oxman AD, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al.for the GRADE Working Group. Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
116. Hanson JW, Myrianthopoulos NC, Sedgwick-Harvey MA, Smith DW. Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. The Journal of Pediatrics 1976;89:662-8.
117. Hauser W, Hesdorffer D. Epilepsy: Frequency, causes and consequences. New York: Demos Publications, 1990.
118. Hernandez-Diaz S, Smith CR, Shen A, Mittendorf R, Hauser WA, Yerby M. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012;78(21):1692-9.
119. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
120. Hill RM, Verniaud WM, Rettig GM, Tennyson LM, Craig JP. Relationship between antiepileptic drug exposure of the infant and developmental potential. In: Janz D, Dam M, Richens A, Bossi L, Helge H, Schmidt D editor(s). Epilepsy, Pregnancy and the Child. New York: Ravens Press, 1982:409-17.
121. Huth H, Steinhausen HC, Helge H. Mental development in children of epileptic parents. In: Janz D, Dam M, Richens A, Bossi L, Helge H, Schmidt D editor(s). Epilepsy, Pregnancy and the Child. New York: Ravens Press, 1982:437-41.
122. Kantola-Sorsa E, Gaily E, Isoaho M, Korkman M. Neuropsychological outcomes in children of mothers with epilepsy. Journal of the International Neuropsychological Society 2007;13(4):642-52.
123. Kirkham J, Dwan K, Altman D, et al.The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365.
124. Lindhout D, Meinardi H, Meijer J, Nau H. Antiepileptic drugs and teratogenesis in two consecutive cohorts: Changes in prescription policy paralleled by changes in pattern of malformations. Neurology 1992;42:94-110.
125. Mawhinney E, Craig J, Morrow J, Russell A, Smithson WH, Parsons L, et al.Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology 2013;80(4):400-5.
126. Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C. Pregnancy outcomes in women with epilepsy: A systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Research 2008;81:1-13.
127. Meador K, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell D, Cohen M, et al.Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine 2009;360:1597-605.
128. Meador KJ, Penovich P, Baker GA, Pennell PB, Bromfield E, Pack A. Antiepileptic drug use in women of childbearing age. Epilepsy and Behavior 2009;15(3):339-43.
129. Meador KJ, Baker GA, Browning N, Cohen M, Clayton-Smith J, Kalayjian LA, et al.Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain 2011;134:396-404.
130. Metcalfe A, Roberts JI, Abdulla F, Wiebe S, Hanson A, Federico P, Jette N. Patient knowledge about issues related to pregnancy in epilepsy: a cross-sectional study. Epilepsy and Behavior 2012;24(1):65-69.
131. Miyazaki K, Narita N, Narita M. Maternal administration of thalidomide or valproic acid causes abnormal serotonergic neurons in the offspring: Implications for pathogenesis of autism. International Journal of Developmental Neuroscience 2005;23:287-97.
132. Moore SJ, Turnpenny, PD, Quinn A, Glover S, Lloyd DJ, Montgomery T, et al.A clinical study of 57 children with fetal anticonvulsant syndromes. Journal of Medical Genetics 2000;37:489-97.
133. Nadebaum C, Anderson V, Vajda F, Reutens D, Barton S, Wood A. The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. Journal of International Neuropsychological Society 2011;17:1-10.
134. Nicolai J, Vles JSH, Aldenkamp AP. Neurodevelopmental delay in children exposed to antiepileptic drugs in utero: A critical review directed at structural study-bias. Journal of the Neurological Sciences 2008;271(1-2):1-14.
135. Rasalam AD, Hailey H, Williams JH, Moore SJ, Turnpenny PD, Lloyd DJ, et al.Charateristics of fetal anticonvulsant syndrome associated autistic disorder. Developmental Medicine and Child Neurology 2005;47(8):551-5.
136. Roberts JI, Metcalfe A, Abdulla F, Wiebe S, Hanson A, Federico P, Jette N. Neurologists' and neurology residents' knowledge of issues related to pregnancy for women with epilepsy. Epilepsy and Behavior 2011;22(2):358-63.
137. Steinhausen HC, Losche G, Koch S, Helge H. The psychological development of children of epileptic parents. I. Study design and comparative findings. Acta Paediatrica 1994;83:955-60.
138. Titze K, Koch S, Helge H, Lehmkuhl U, Rauh H, Steinhausen H-C. Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental Medicine and Child Neurology 2008;50(2):117-22.
139. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, et al.Dose-dependent risk of malformations with antiepileptic drugs: An analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology 2011;10(7):609-17.
140. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, et al.Dose-dependent risk of malformation with antiepileptic drugs: An analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology 2011;10(7):609-17.
141. Veiby G, Engelsen BA, Gilhus NE. Early child development and exposure to antiepileptic drugs prenatally and through breastfeeding: a prospective cohort study on children of women with epilepsy. JAMA Neurology 2013;70(11):1367-74.
142. Williams P, Hersh J. A male with fetal valproate syndrome and autism. Developmental Medicine and Child Neurology 1997;39:632-4.
143. Winter R, Donnai D, Burn J, Tucker S. Fetal valproate syndrome: Is there a recognisable phenotype?. Journal of Medical Genetics 1987;24:692-5.
144. Yerby MS. Pregnancy, teratogenesis and epilepsy. Neurological Clinics 1994;12:749-71.
145. Adab N, Tudur Smith C, Vinten J, Williamson PR, Winterbottom JB. Common antiepileptic drugs in pregnancy in women with epilepsy (Review). Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD004848].